Citadel Advisors’s TScan Therapeutics TCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $318K | Buy |
218,987
+164,595
| +303% | +$239K | ﹤0.01% | 4554 |
|
|
2025
Q1 | $75.1K | Sell |
54,392
-88,225
| -62% | -$122K | ﹤0.01% | 5243 |
|
|
2024
Q4 | $434K | Buy |
+142,617
| New | +$434K | ﹤0.01% | 4149 |
|
|
2024
Q3 | – | Sell |
-157,963
| Closed | -$924K | – | 6688 |
|
|
2024
Q2 | $924K | Buy |
157,963
+146,531
| +1,282% | +$857K | ﹤0.01% | 3122 |
|
|
2024
Q1 | $90.8K | Buy |
+11,432
| New | +$90.8K | ﹤0.01% | 5115 |
|
|
2021
Q4 | – | Sell |
-11,922
| Closed | -$99K | – | 7170 |
|
|
2021
Q3 | $99K | Buy |
+11,922
| New | +$99K | ﹤0.01% | 5885 |
|